Loading…

Immunovant IncIMVTCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Biotech developing FcRn-inhibitor antibodies for autoimmune diseases, competing in the same class as argenx's Vyvgart.

Momentum neutral 42
Mkt cap
$6.86B
US dollars, full cap
Free float
41%
of shares outstanding
$/day
$43.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 9.8%
Hurdle
n/a
no reverse DCF
Next earnings
90 days
16 Feb 2027
Close · USD$33.17
1D-0.1%
1W-10.4%
1M+16.0%
3M-25.2%
6M-6.7%
YTD+30.5%
1Y+36.5%
ATR %4.8%
Beta1.61
52w lowhigh27.0% off high

What Immunovant does

Biotech developing FcRn-inhibitor antibodies for autoimmune diseases, competing in the same class as argenx's Vyvgart.

Has no product to sell, so its costs are paid from money raised from investors; Roivant, the company that founded it, is the largest shareholder. Its value rests on clinical-trial results for IMVT-1402, which it has put ahead of batoclimab, before any route to market through approval and later sales.

Products and services

  • Batoclimab (FcRn inhibitor, multiple autoimmune indications)
  • IMVT-1402 (next-gen FcRn inhibitor)

Customers

  • Neurologists/immunologists treating autoimmune dis

Where it sits in the supply chain

  • Healthcare
  • Biotechnology
  • Autoimmune antibody drug discovery and…

What could go right

  • Multiple simultaneous indication trial readouts
  • Differentiated dosing/formulation versus competitors

What could go wrong

  • Pre-revenue, binary late-stage trial risk
  • Crowded, well-funded FcRn-inhibitor competitive field

Moat: narrow (IP / patents). A differentiated, potentially self-administered FcRn inhibitor competing against an already-approved class leader.

Headquarters: New York, New York, US · Founded: 2018 · Employees: 315

Named competitors

Immunovant at a glance

Size Immunovant (IMVT) is a United States Health Care company (Biotechnology) with a market value of $6.86B, the 967th largest of 3,085 United States companies the cockpit tracks. Shares closed at $33.17 on 18 Nov 2026.

Performance Over six months the shares fell 6.7%, against +10.3% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 21 in its peer set.

Short interest Short interest is 9.0% of the free float (30 Oct 2026).

Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 110IMVT 97
Six months, rebased to 100: Immunovant against the median of its 20 peers (local-currency closes).

Immunovant financials

Reported figures in USD; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$378,000-$409,000-$377,000-$231,000-$1.32M
EBITDA-$538M-$532M-$438M-$270M-$207M
Net income-$509M-$506M-$414M-$259M-$211M
Free cash flow-$395M-$407M-$377M-$215M-$188M
Capital expenditure$8,000$8,000$759,000$360,000$197,000
Total debt$0$72,000$98,000$138,000$1.57M

Quarterly statements and history in the cockpit →

Immunovant competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%AXSMCGONKODTXGARWRTWSTSRRKSMMTCAIANTHEM1548196170300122PCVXKRYS300347COGTDNTH002422ADPTIMVT6-month return →1-month return →
Up and to the right = strong over both horizons. Immunovant is the large dot.

Immunovant competitors and peer comparison

Head to head with its named competitors (IMVT vs ARGX vs JNJ vs AZN.L)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Immunovant IMVT$6.86B-7%n/an/an/an/a
argenx SE Sponsored ADR ARGX$59.1B+17%+71%29%10.3×11.7%
Johnson & Johnson JNJ$656B+20%+8%26%6.9×3.7%
AstraZeneca AZN.L$278B-2%+5%23%5.0×14.4%
Regeneron Pharmaceuticals REGN$97.8B+46%+19%30%5.4×-1.1%
Biohaven BHVN$1.95B+46%n/an/an/an/a
Dianthus Therapeutics DNTH$4.73B-5%-12%-8,684%1,432.1×n/a

How Immunovant compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Immunovant against its 20 peers (data as of 18 Nov 2026)
MeasureIMVTPeer medianRank in peer set
1-month return+16.0%-9.3%5th highest of 21
6-month return-6.7%+10.3%6th lowest of 21
Distance from 52-week high-27.0%-34.3%8th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Immunovant IMVTUnited States$6.86B-7%n/an/an/an/an/a
Axsome Therapeutics AXSMUnited States$7.05B-42%+54%-19%8.0×n/an/a
CG Oncology CGONUnited States$7.15B+24%+184%-4,294%1,000.7×n/an/a
Kodiak Sciences KODUnited States$6.40B+170%n/an/an/an/an/a
10x Genomics TXGUnited States$7.51B+138%-4%-11%11.3×47.2%+16.6%
Arrowhead Pharmaceuticals ARWRUnited States$6.09B-44%-46%-157%14.0×n/an/a
Twist Bioscience TWSTUnited States$7.93B+117%+22%-29%16.2×n/an/a
Scholar Rock SRRKUnited States$5.86B-1%n/a-71,732%9,900.4×n/an/a
Summit Therapeutics SMMTUnited States$8.40B-41%n/an/an/an/an/a
Caris Life Sciences CAIUnited States$5.59B+24%+61%13%5.0×18.2%+61.5%
Anthem Biosciences ANTHEM.NSIndia$5.51B+16%-1%35%24.9×36.9%+26.2%
Genscript Biotech 1548.HKHong Kong$8.69B+133%+53%12%9.8×36.9%+19.8%
ALTEOGEN 196170.KSSouth Korea$8.80B-56%+61%53%35.1×24.6%+38.5%
Chongqing Zhifei Biological Products 300122.SZChina$5.28B-1%-28%-210%5.3×-6.5%-10.0%
Vaxcyte PCVXUnited States$9.26B+24%n/an/an/an/an/a
Krystal Biotech KRYSUnited States$9.34B+4%+26%48%18.0×13.1%+26.0%
Hangzhou Tigermed Consulting 300347.SZChina$4.88B-2%+16%10%4.8×25.9%+16.4%
Cogent Biosciences COGTUnited States$4.84B-16%n/an/an/an/an/a
Dianthus Therapeutics DNTHUnited States$4.73B-5%-12%-8,684%1,432.1×n/an/a
Sichuan Kelun Pharmaceutical 002422.SZChina$10.1B+35%0%9%3.7×6.2%+2.3%
Adaptive Biotechnologies ADPTUnited States$4.61B+104%+18%-16%15.8×n/an/a

Questions

Who are Immunovant's main competitors?
Named competitors: argenx (Vyvgart) (ARGX), UCB (private or unlisted), Johnson & Johnson (nipocalimab) (JNJ), AstraZeneca (AZN.L), Regeneron Pharmaceuticals (REGN), Biohaven (BHVN). The cockpit's measured peer set (industry) also includes Axsome Therapeutics (AXSM), CG Oncology (CGON), Kodiak Sciences (KOD), 10x Genomics (TXG), Arrowhead Pharmaceuticals (ARWR), Twist Bioscience (TWST).
How has Immunovant stock performed?
Over six months to 18 Nov 2026 the shares returned -6.7% against +10.3% for the median peer; over one year +36.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.